Journal of Rheumatology
type: Periodical
type: Information Content Entity
type: Journal
type: Thing
type: Document
type: Collection
type: Continuant
type: Entity
publication venue for: Methotrexate therapy in childhood systemic lupus erythematosus
type: Generically Dependent Continuant

Document
type: Class

Methotrexate therapy in childhood systemic lupus erythematosus
type: Thing
pmid: 8496874
related by: authorship 1464
type: Generically Dependent Continuant
date time value: article date 347
volume: 20
issue: 4
crisid: 347
has publication venue: Journal of Rheumatology
most specific type: Document
estado: published
most specific type: Article
related by: authorship 1465
abstract: We evaluated the therapeutic potential of methotrexate (MTX) in patients with systemic lupus erythematosus (SLE). Their serious disease ruled out further treatment with prednisone or prednisone plus cyclophosphamide. Low dose oral MTX (5-10 mg/week) was added to the therapy (prednisone or prednisone plus cyclophosphamide) of 10 selected patients with SLE. Eight of them showed marked improvement and we were able to taper prednisone and completely discontinue cyclophosphamide therapy. Our results suggest that the use of oral MTX in low, weekly doses can be useful as adjunctive therapy for selected cases of childhood SLE.
page end: 733
type: Information Content Entity
type: Document
origen: scopus
related by: authorship 1463
page start: 731
related by: authorship 1466
type: Continuant
e iscopus: 2-s2.0-0027174538
type: Article
freetext keyword: childhood; methotrexate; systemic lupus erythematosus cyclophosphamide; methotrexate; prednisone; adolescent; article; clinical article; female; gastrointestinal disease; human; male; oral drug administration; priority journal; school child; systemic lupus erythematosus; Administration, Oral; Adolescent; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Combinations; Human; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Treatment Outcome
type: Entity
chemicalscas: cyclophosphamide, 50-18-0; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; prednisone, 53-03-2; Cyclophosphamide, 50-18-0; Drug Combinations; Methotrexate, 59-05-2; Prednisone, 53-03-2

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Methotrexate therapy in childhood systemic lupus erythematosus - http://orbis.uaslp.mx/vivo/individual/scopus346
rights: termsOfUse
date: 2026-08-24T21:49:44
publisher: vivo
type: Document

Article
type: Class

Information Content Entity
type: Class